Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphomas, including diffuse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Transformed Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• XPOVIO (selinexor)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING